TIDMDDDD
4d Pharma PLC
25 July 2019
Non-Regulatory
4D pharma plc
(the "Company" or "4D")
Oncology Programmes Update
4D pharma plc (AIM: DDDD), a pharmaceutical company leading the
development of Live Biotherapeutics, today announces an update on
its oncology programmes. New preclinical data on the Company's
oncology candidates, MRx0518 and MRx1299, were presented at 1(st)
Microbiome Movement Oncology Response Summit in Boston, USA by
Research Director Imke Mulder. A clinical progress update on
MRx0518 was also provided by 4D's Chief Scientific Officer, Alex
Stevenson.
MRx1299
MRx1299 is a second-generation Live Biotherapeutic identified by
4D's MicroRx(R) discovery platform. One of the target host pathways
identified for this Live Biotherapeutic is its potent histone
deacetylase (HDAC) inhibition mediated by bacterial short-chain
fatty acids (SCFAs). HDAC inhibition is thought to have multiple
modes of anti-cancer activity, acting on both tumour and immune
cells. Treatment with MRx1299 and its metabolites gives cytotoxic T
lymphocytes the ability to reduce tumour growth in preclinical
cancer models.
MRx0518
MRx0518, the Company's lead Live Biotherapeutic candidate in
oncology, induces strong innate and adaptive immune responses in
vitro and in vivo. New data presented demonstrates the ability of
orally administered MRx0518 to modulate the frequency of immune
cell populations with anti-tumour activity in the gastrointestinal
tract, systemically and in the tumour microenvironment, acting
through signalling pathways known to drive anti-cancer
immunity.
The Company has previously published data on the mechanism of
action of MRx0518 (Lauté-Caly et al. 2019), demonstrating that the
bacterial flagellin protein, FliC, strongly activates
immunostimulatory NF-<KAPPA>B signalling, via the TLR5
receptor. Research presented at the conference indicates a role for
additional host receptors, including TLR9, in mediating the
immuno-stimulatory effects of MRx0518.
Alex Stevenson, 4D's Chief Scientific Officer, commented: "The
identification of our new Live Biotherapeutic candidate, MRx1299,
strengthens our leading oncology portfolio and expands the scope of
oncology indications for our Live Biotherapeutics. MRx1299 has a
different mechanism of action to MRx0518 and as such may be
suitable for the treatment of different types of cancer. Studies of
MRx1299's efficacy in preclinical models of additional tumour types
are ongoing, as is scale-up and process development."
He added, "The additional preclinical data on MRx0518
strengthens our knowledge of its mechanism of action and capacity
to launch an immune response against cancer cells. In parallel,
data generated from our ongoing clinical studies will assess the
ability of MRx0518 to induce these anti-tumour immunological
effects in patients. Our Phase I/II study of MRx0518 in combination
with KEYTRUDA(R) (pembrolizumab) in patients with solid tumours
will provide us with specific biomarker data from both parts of the
study. We anticipate the first of this data to be available by the
end of 2019."
A copy of the presentations given can be found at
https://www.4dpharmaplc.com/en/newsroom/posters-and-publications
For further information please contact:
4D
Duncan Peyton, Chief Executive Officer + 44 (0)113 895 0130
Fay Weston, Head of Investor Relations + 44 (0)7990 381713
N+1 Singer - Nominated Adviser and Joint
Broker +44 (0) 20 7496 3000
Aubrey Powell/ Justin McKeegan/ Alex Bond
(Corporate Finance)
Tom Salvesen (Corporate Broking)
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson /Phil Walker
About 4D
Founded in February 2014, 4D is a world leader in the
development of Live Biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacterium, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform that rationally identifies novel bacteria
based on a deep understanding of function and mechanism. 4D's Live
Biotherapeutic products are orally delivered single strains of
bacteria that are naturally found in the healthy human gut. 4D has
four clinical studies in progress, namely a Phase II clinical study
of Blautix in Irritable Bowel Syndrome, a Phase I/II study of
MRx0518 in combination with KEYTRUDA(R) (pembrolizumab) in solid
tumours, a Phase I study of MRx0518 in a neoadjuvant setting for
patients with solid tumours and a Phase I/II study of MRx-4DP0004
in asthma. Other focus programmes include disease areas such as CNS
disease.
About Cancer
Cancer is a group of diseases involving abnormal cell growth
with the potential to invade or spread to other parts of the body.
Globally, it is estimated that there were around 18 million new
cases in 2018 and that almost 10 million people died of cancer,
making it the leading cause of death world-wide. The number of new
cancer cases per year is expected to rise to 23.6 million by 2030.
The global market for oncology drugs is expected to reach $111.9bn
by 2020.
The microbiome has been implicated in cancer treatment and
response in a range of clinical settings including standard
chemotherapy. The microbiome profile of patients has been
demonstrated to drive response to anti-PD-1 therapy in both
melanoma and non-small cell lung cancer.
About MRx0518
As both a monotherapy and in combination settings MRx0518 has
demonstrated robust efficacy as an immuno-stimulant and anti-tumour
agent in multiple tumour models such as breast cancer, renal cell
carcinoma and lung cancer. MRx0518 acts on both the innate and
adaptive immune system to induce a unique response mediated by
TLR5.
The Company is investigating MRx0518 across a range of clinical
cancer settings in 2019. In collaboration with Merck, Sharpe &
Dohme (Merck & Co. Inc), MRx0518 is being evaluated in an open
label Phase I/II study of MRx0518 in combination with KEYTRUDA(R)
(pembrolizumab) in patients with solid tumours who have failed
prior anti-PD-1 therapy. A Phase Ib randomised, placebo-controlled
study of MRx0518 as a monotherapy in a neoadjuvant setting for
solid tumours has also commenced.
For more information about the clinical studies please visit
https://clinicaltrials.gov/ct2/show/NCT03851250
https://clinicaltrials.gov/ct2/show/NCT03934827
About MRx1299
MRx1299 is a second generation Live Biotherapeutic identified
through 4D's MicroRx(R) platform. MRx1299 has strong histone
deacetylase (HDAC) inhibition activity. The HDAC pathways are
implicated in the development and growth of a range of solid and
haematologic cancers. MRx1299 has demonstrated the ability to
inhibit tumour growth in models of melanoma and CRC.
For more information, refer to https://www.4dpharmaplc.com/
KEYTRUDA(R) is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ,
USA
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEALXLALXNEFF
(END) Dow Jones Newswires
July 25, 2019 02:02 ET (06:02 GMT)
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni 4d Pharma (LSE:DDDD)
Storico
Da Mar 2023 a Mar 2024